Current understanding of the Alzheimer's disease-associated microbiome and therapeutic strategies.

Authors:
Seo DO; Holtzman DM.

Journal:
Exp Mol Med

Publication Year: 2024

DOI:
10.1038/s12276-023-01146-2

PMCID:
PMC10834451

PMID:
38172602

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Exp Mol Med

Abbreviation: Exp Mol Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Molecular Biology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
4-1BB immunotherapy: advances and hurdles.
Singh R; Kim YH; Lee SJ and 2 more (2024) - Transparency Score: 3/6
Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on …
Choi BJ; Park MH; Jin HK and 1 more (2024) - Transparency Score: 3/6
Baf-mediated transcriptional regulation of teashirt is essential for the development of neural prog…
Ko BS; Han MH; Kwon MJ and 13 more (2024) - Transparency Score: 3/6
Cost and time-efficient construction of a 3'-end mRNA library from unpurified bulk RNA in a single …
Choi J; Hyun J; Hyun J and 3 more (2024) - Transparency Score: 3/6
CYB5R3 functions as a tumor suppressor by inducing ER stress-mediated apoptosis in lung cancer cell…
Im JY; Kim SJ; Park JL and 15 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests D.M.H. is a cofounder of C2N Diagnostics, LLC, and is on the scientific advisory board and/or consults for Genentech, Denali, C2N Diagnostics, Cajal Neurosciences, and Asteroid. D.M.H. is an inventor on a patent licensed by Washington University to NextCure on the therapeutic use of anti-apoE antibodies. The Holtzman laboratory receives research grants from the National Institutes of Health, the Cure Alzheimer’s Fund, the Rainwater Foundation, the JPB Foundation, the Good Ventures Foundation, the GHR Foundation, Novartis, Eli Lilly, and NextCure. The authors declare no other competing interests."

Evidence found in paper:

"Supported by the Good Ventures Foundation and NIH grant RF1NS090934."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025